-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5
Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5
Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.
(See https://remedium.ru/industry/pharmindustry/analysis/Reyting-predpriyatiy-farmpromyshlennosti-po-obemu-valovoy-pribyli-za-2020-god/)
Remedium's ratings are calculated based on the annual financial statements of 90 companies representing the largest pharmaceutical companies in the country. Remedium's ratings only include profitable businesses. According to these standards, PJSC Kraspharma entered the top five largest companies in terms of gross profit growth dynamics, outpacing the long-term leaders of this rating by ten times. The company also entered the TOP-30 of the largest pharmaceutical companies in terms of gross profit, retaining its position since 2019.
Also, according to the monthly monitoring of the Russian pharmaceutical market compiled by DSM Group, for the first nine months of 2020 PJSC Kraspharma entered the TOP-5 rating of manufacturers of antibacterial agents for systemic use. During the reporting period, PJSC Kraspharma increased the volume of sold antibiotics by more than 40%. For more details see:
https://cyberleninka.ru/article/n/obzor-prodazh-antibakterialnyh-preparatov-po-itogam-9-mesyatsev-2020-goda/viewer
https://www.kommersant.ru/doc/4626162
https://www.elibrary.ru/title_about_new.asp?id=9038
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate," or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.
塞浦路斯尼科西亚,2021年11月19日(环球通讯社)拉法尔玛制药公司(Rafarma PharmPharmticals,Inc.) 场外交易:(拉法)据报道,PJSC KrasPharma在2020年底进入了2020年俄罗斯最具活力和最大的制药公司前5名,显示出令人难以置信的增长速度,与2019年相比净利润增长了220.9%。具体地说,KrasPharma从2019年底的5563,056美元升至2020年底的17,853,905美元。这一增长在2021年第三季度出版的俄罗斯权威行业出版物“补救”(Remedium)的评级中有所体现。
(See https://remedium.ru/industry/pharmindustry/analysis/Reyting-predpriyatiy-farmpromyshlennosti-po-obemu-valovoy-pribyli-za-2020-god/)
(请参阅https://remedium.ru/industry/pharmindustry/analysis/Reyting-predpriyatiy-farmpromyshlennosti-po-obemu-valovoy-pribyli-za-2020-god/)
Remedium's ratings are calculated based on the annual financial statements of 90 companies representing the largest pharmaceutical companies in the country. Remedium's ratings only include profitable businesses. According to these standards, PJSC Kraspharma entered the top five largest companies in terms of gross profit growth dynamics, outpacing the long-term leaders of this rating by ten times. The company also entered the TOP-30 of the largest pharmaceutical companies in terms of gross profit, retaining its position since 2019.
Remedium的评级是根据代表美国最大制药公司的90家公司的年度财务报表计算得出的。Remedium的评级只包括盈利业务。根据这些标准,PJSC KrasPharma进入了毛利增长动力最大的前五家公司,超过了这一评级的长期领先者十倍。该公司还进入了毛利润最大的30家制药公司之列,自2019年以来一直保持着这一地位。
Also, according to the monthly monitoring of the Russian pharmaceutical market compiled by DSM Group, for the first nine months of 2020 PJSC Kraspharma entered the TOP-5 rating of manufacturers of antibacterial agents for systemic use. During the reporting period, PJSC Kraspharma increased the volume of sold antibiotics by more than 40%. For more details see:
此外,根据帝斯曼集团(DSM Group)编制的俄罗斯药品市场月度监测,2020年前9个月,PJSC KrasPharma进入了全身使用抗菌剂制造商的前5名。在本报告所述期间,PJSC KrasPharma将抗生素的销售量增加了40%以上。有关更多详细信息,请参阅:
https://cyberleninka.ru/article/n/obzor-prodazh-antibakterialnyh-preparatov-po-itogam-9-mesyatsev-2020-goda/viewer
https://www.kommersant.ru/doc/4626162
https://www.elibrary.ru/title_about_new.asp?id=9038
Https://cyberleninka.ru/article/n/obzor-prodazh-antibakterialnyh-preparatov-po-itogam-9-mesyatsev-2020-goda/viewer
Https://www.kommersant.ru/doc/4626162
Https://www.elibrary.ru/title_about_new.asp?id=9038
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate," or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
前瞻性陈述:本新闻稿包含1934年证券交易法第21E节所指的“前瞻性陈述”。除本文包含的历史事项外,本新闻稿中的陈述均为前瞻性陈述。在不限制前述一般性的情况下,诸如“可能”、“将”、“到”、“计划”、“预期”、“相信”、“预期”、“打算”、“可能”、“将”、“估计”或“继续”等词语或其负面的其他变体或类似术语旨在识别前瞻性陈述。前瞻性陈述涉及已知和未知的风险、不确定因素和其他因素,这些风险、不确定性和其他因素可能导致我们的实际结果、表现或成就与前瞻性陈述明示或暗示的任何未来结果、表现或成就大不相同。此外,前瞻性陈述仅代表我们管理层截至本文发布之日的信念和假设。有关可能导致实际结果与这些前瞻性陈述大不相同的因素的更多信息,请参阅公司向场外交易市场提交的文件。除非法律要求,否则我们没有义务公开更新这些前瞻性陈述,或更新实际结果可能与这些前瞻性陈述中预期的结果大不相同的原因,即使未来有新的信息。
For more information contact:
RAFARMA
(307) 429-2029
如需更多信息,请联系:
拉法尔马
(307) 429-2029
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧